Authors

• Lucía Castillo (ORCID: https://orcid.org/0000-0002-6524-4984)
• Aung Naing (ORCID: https://orcid.org/0000-0002-4803-8513)
• Mohamed H. Derbala (ORCID: https://orcid.org/0000-0002-0420-3521)
• Evan Kwiatkowski (ORCID: https://orcid.org/0000-0001-8398-8429)
• Serdar A. Gurses (ORCID: https://orcid.org/0000-0002-8781-4554)
• Petra Budde (ORCID: https://orcid.org/0000-0001-8991-3495)
• Siqing Fu (ORCID: https://orcid.org/0000-0002-1933-0419)
• Behnaz Ahangarian Abhari
• F. Meric-Bernstam
• D.S. Hong
• Justin T. Moyers (ORCID: https://orcid.org/0000-0001-5139-1652)
• Joud Hajjar (ORCID: https://orcid.org/0000-0003-4633-1043)
• Abdulrazzak Zarifa (ORCID: https://orcid.org/0000-0002-4649-2456)
• Mohamed A. Gouda (ORCID: https://orcid.org/0000-0003-4829-6739)
• Bettzy Stephen (ORCID: https://orcid.org/0000-0003-1653-2012)
• H-D Zucht
• Jeffrey How (ORCID: https://orcid.org/0000-0003-1446-9574)
• E. Rodriguez
• Matthias Bräutigam
• Ann-Sophie Lindemann

Institutions

• The University of Texas MD Anderson Cancer Center (US)
• Angeles Clinic and Research Institute (US)
• Texas Children's Hospital (US)
• The University of Texas Health Science Center at Houston (US)

Publication Details

Journal

ESMO Open

Published

2025-08-01

DOI

https://doi.org/10.1016/j.esmoop.2025.105518

Citations

1

Primary Topic

Cancer Immunotherapy and Biomarkers

Type

article

Field-Weighted Citation Impact

1.05

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• Pfizer
• Sanofi
• American Society of Clinical Oncology
• Karyopharm Therapeutics
• Regeneron Pharmaceuticals
• Cholangiocarcinoma Foundation
• Society for Immunotherapy of Cancer
• Millendo Therapeutics
• Mersana Therapeutics
• Incyte
• Calithera Biosciences
• NGM Biopharmaceuticals
• Seagen
• European Organisation for Research and Treatment of Cancer
• European Society for Medical Oncology
• STCube
• Servier
• EMD Serono
• University of Texas MD Anderson Cancer Center
• National Cancer Institute
• Janssen Biotech